On February 17, 2026, Mereo BioPharma Group plc received a Nasdaq notification letter stating its ADSs failed to maintain a $1.00 minimum bid price over 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). The Company has 180 days until August 17, 2026, to regain compliance, with trading under 'MREO' continuing uninterrupted.
Key takeaways
Received Nasdaq Notification Letter on February 17, 2026 for bid price non-compliance
ADSs failed to maintain $1.00 minimum bid price for 30 consecutive business days
Compliance period ends August 17, 2026 (180 calendar days)
Regain compliance by achieving $1.00 closing bid price for 10 consecutive business days
Potential additional 180-day grace period if other listing standards met
No immediate delisting; ADSs continue trading under 'MREO'